Kura Oncology (KURA) EBITDA Margin (2025 - 2026)
Kura Oncology (KURA) reported EBITDA Margin of 409.18% for Q1 2026, down 360.0% year-over-year from 157.38% in Q1 2025, and up 12.31% on a QoQ basis from 466.62% in Q4 2025.
Kura Oncology (KURA) has 2 years of EBITDA Margin data on file, last reported at 409.18% in Q1 2026.
- Quarterly EBITDA Margin fell 360.0% year-over-year to 409.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 413.08% (changed N/A YoY) and the FY2025 annual result came in at 412.56%, down 9345.0% from the prior year.
- EBITDA Margin advanced to 409.18% in Q1 2026 per KURA's latest filing, from 466.62% in the prior quarter.
- Across five years, EBITDA Margin topped out at 356.19% in Q3 2025 and bottomed at 466.62% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | -409.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -409.18% |
| Dec 31, 2025 | -466.62% |
| Sep 30, 2025 | -356.19% |
| Jun 30, 2025 | -434.23% |
| Mar 31, 2025 | -405.58% |